At Cambridge Therapeutics in Teaneck, New Jersey, Chairman John Klein and his company work to manufacture high-quality, high-adherence medication packaging and other medical products. In addition to his work at Cambridge Therapeutics, John Klein has given extensively of his time to a number of educational and healthcare-focused nonprofit organizations, and has served as a trustee and past president of the Dwight-Englewood School, one of New England’s premier private preparatory academies.
Also known as D-E, the school currently serves close to 1,000 students, offering a comprehensive, co-educational learning experience for preschool to high school students. The school is proud of its diversity, with students coming from more than 80 distinct regions in New York and New Jersey.
Like many of the nation’s elite schools, D-E maintains a strong focus on ethics, a course required for every student in 10th grade. Among the reasons for teaching ethics at this level are the opportunities it offers students to encounter opposing viewpoints, to learn to identify faulty logic and rhetoric, and to be future leaders in an increasingly complex world.
Students in this one-semester class learn to think critically about important philosophical issues through discussion, intense essay-writing, and readings of case studies. Associated electives offered at the advanced level include honors courses on ancient and modern philosophy, as well as bioethics.
With decades of experience in the pharmaceutical and health care industries, John Klein currently serves as the chairman of Cambridge Therapeutics. Before his successful career at Cambridge Therapeutics, John Klein earned a master of business administration from the Roosevelt University Heller College of Business.
In October 2018, the Heller College of Business unveiled its newly redesigned Financial Trading Room on the 12th floor of the Wabash Building. The state-of-the-art trading room has 16 Bloomberg Terminals, advanced financial trading software, and touch-screen presentation boards. In the lab, students have access to historical and real-time data about publicly traded companies. In addition, the trading room now supports live video feeds between the Chicago and Schaumburg campuses.
Roosevelt is among only 21 percent of educational institutions equipped with its own financial lab. The newly renovated lab encourages students to apply classroom skills to real-life scenarios, which will better prepare them for the job market, said Asghar Sabbaghi, dean of the Heller College of Business.
Possessing three decades of experience in the pharmaceutical industry, John Klein serves as the chairman of Teaneck, New Jersey-based Cambridge Therapeutics. John Klein is responsible for guiding Cambridge Therapeutics in the development of combination therapies and novel drug delivery systems.
Novel drug delivery systems involve innovative approaches to the delivery of drugs. The process used to deliver drugs to patients can significantly impact their effectiveness and safety. For instance, many pharmaceuticals have an optimum concentration range that provides a maximum amount of therapeutic benefit, while higher amounts can be toxic and lower amounts may result in no benefit.
To maximize the health benefits of pharmaceutical therapies and reduce harmful side effects, researchers are developing new drug delivery systems that are based on interdisciplinary research in fields such as bioconjugate chemistry, polymer science, molecular biology, and pharmaceutics. Some of the techniques used in novel drug delivery systems include cell ghosts, microparticles comprised of biodegradable or insoluble polymers, microcapsules, lipoproteins, soluble polymers, and other delivery techniques.
The founder and chairman of Cambridge Therapeutics, John Klein draws on more than two decades of experience as a senior executive with companies such as Zenith Laboratories, Ivax, and NovaDel Pharma. During his career, Cambridge Therapeutics founder John Klein has gained a deep understanding of the U.S. Food and Drug Administration’s (FDA) approval process.
Before applying for FDA approval to market a new drug, sponsors must file a New Drug Application (NDA), in which they are required to detail data and analyses regarding the drug’s manufacturing process, pharmacology, dosage, and toxicology, as well as any human and animal studies. Upon the submission of an NDA, the FDA can take as long as 60 days to decide if it is going to file it for further review or reject it on the basis that it requires additional information.
If filed for review, the NDA is then evaluated by the FDA’s Center for Drug Evaluation and Research (CDER), which can take up to 6 months to act on priority drugs and 10 months for all other drugs. The CDER can then either approve or reject the drug, or issue an approvable letter regarding the drug which states minor deficiencies that need to be corrected before ultimate approval. The NDA process has served as the basis for regulating new drugs in the United States since 1938.
As the chairman of New Jersey-based Cambridge Therapeutics, John Klein leverages more than two decades of experience in the pharmaceutical industry to manage the development of combination drug therapies. Over the course of his career, John Klein has received recognition as an Outstanding CEO from Mitchell & Company and has been awarded Bronze Standing by the Wall Street Transcript for his role in enhancing enterprise value.
Established in 1963 to serve the financial community, the Wall Street Transcript is a publication and website that features interviews with CEOs and executives from numerous public companies. Readers can access a searchable database with more than 25,000 CEO interviews, as well as investing strategy and industry reports. Regular contributors include prominent investment houses such as Goldman Sachs, Merrill Lynch, and Morgan Stanley.
Named by Forbes as the Best Web Site Publication for Stock Picking, the Wall Street Transcript has approximately 200,000 readers each month. To browse content and interviews, or for information on subscriptions, visit www.twst.com.
An accomplished pharmaceutical executive who heads Cambridge Therapeutics, John Klein has received the Ellis Island Medal of Honor and Business Week’s Corporate Turnaround of the Year recognition, in addition to earning 11th place on Forbes’ list of Top 100 CEOs. As chairman and CEO of Cambridge Therapeutics, John Klein oversees all strategic planning in relation to the distribution of drugs and combination therapies to patients around the nation. Prior to creating this company in 2011, he developed Dava Pharmaceutical Company from the ground up and also headed Ivax Pharmaceutical and Zenith Laboratories, Inc. He additionally chaired the Worldwide Generics Pharmaceutical Industry Association.
Involved in his local community, he serves as a trustee of Hackensack Meridian Health Hospitals, as well as of the Dwight-Englewood School. Formerly, he served as president of the board at this college preparatory academy.
He holds an MBA in in finance from Roosevelt University and also completed coursework on executive decision-making in relation to marketing at the Wharton School of the University of Pennsylvania.